Pharmaceutical Technology21m
Risk adjusted net present value: What is the current valuation of Roche’s CT-388?
The revenue for CT-388 is expected to reach an annual total of $179 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology25m
Risk adjusted net present value: What is the current valuation of Armata Pharmaceuticals’s APSA-02?
APSA-02 is a biologic commercialized by Armata Pharmaceuticals, with a leading Phase II program in Bacteremia.
Pharmaceutical Technology25m
Risk adjusted net present value: What is the current valuation of I-Mab’s Givastomig?
The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology25m
Risk adjusted net present value: What is the current valuation of PTC Therapeutics’s PTC-518?
PTC Therapeutics discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren), ...
Pharmaceutical Technology25m
Risk adjusted net present value: What is the current valuation of Sarepta Therapeutics’s SRP-5051?
Sarepta Therapeutics (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic ...
Pharmaceutical Technology27m
Risk adjusted net present value: What is the current valuation of Cardiol Therapeutics’s Cannabidiol 1?
Cannabidiol 1 is a small molecule commercialized by Cardiol Therapeutics, with a leading Phase II program in Pericarditis.
Pharmaceutical Technology28m
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Eneboparatide?
Eneboparatide is a recombinant peptide commercialized by AstraZeneca, with a leading Phase III program in Hypoparathyroidism.
Pharmaceutical Technology32m
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Zilganersen Sodium?
Ionis Pharmaceuticals (Ionis), formerly Isis Pharmaceuticals, focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, ...